Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercialising potential best in class oncology and CNS therapeutics, has significantly expanded its intellectual property (IP) around isoquinolinamine, a class of potent anti-cancer compounds. Rexahn has been issued a continuation patent US 8,314,123 for US 8,034,829 to cover more new isoquinolinamine compounds and their pharmaceutical composition and method for producing an anti-tumour effect.

“Our pre-clinical R&D efforts continually demonstrate that isoquinolinamine compounds provide potent anti-tumour activities in several human cancer cell lines, such as breast, prostate, colon, ovary, kidney, pancreas, glioblastoma and melanoma. With this most recent patent, Rexahn is strongly positioned to develop this emerging class of exciting oncology compounds into novel drugs,” said Rick Soni, president of Rexahn.